Dr. Anna Walkins

I

s a Clinician Scientist at the Institute of Cancer Research, London, and an Honorary Consultant in Clinical Oncology at the Royal Marsden, where she treats prostate and bladder cancers. Her research combines human translational science with pre-clinical models to investigate how different features of the tumour microenvironment, including non-cancerous cells, might help prostate and bladder tumours survive after radiotherapy. Dr. Wilkins is a Project Leader for the ROBIN MCT at the Royal Marsden/Institute of Cancer Research helping to coordinate the MCT internationally. This includes coordination of scoring Tumour Cell Density and ImmunoScore in international and European centers respectively.